In vitro sensitivity of various human tumors to 1-beta-d-arabinofuranosy icy tosine and n4-behenoy 1-1-beta-d-arabinof uranosylcy tosine

Yoshihiko Maehara, Tetsuya Kusumoto, Hiroki Kusumoto, Hideaki Anai, Keizo Sugimachi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The sensitivities to 1-β-D-arabinofuranosylcytosine (ara-C) and N4-behe-noyl-1-β-D-arabinofuranosylcytosine (BH-AC), a masked compound of ara-C, were determined in 33 human tumor tissues (11 gastric, 6 colorectal cancers and 16 malignant lymphomas), using the in vitro succinate dehydrogenase inhibition test. The succinate dehydrogenase (SD) activity of the tumor tissues was assayed following exposure to the drug at 8.8 or 88 μM for 3 days and the sensitivity was considered positive when the SD activity decreased to below 50% of that of the control cells at 88 μM. The SD activity decreased little at 8.8 μM and decreased individually at 88 μM. The mean of the SD activity at 88 μM was 65.7 ± 11.5% for ara-C and 61.4 ± 14.5% for BH-AC in gastrointestinal cancers, and 63.8 ± 16.0% for ara-C and 58.3 ± 18.3% for BH-AC in malignant lymphomas with a statistically significant difference (p < 0.05). BH-AC is converted to ara-C for exertion of the cytotoxic effect and apositive correlation was noted between the SD activities of ara-C and BH-AC (r = 0.825 at88 μM). The chemosensitivity varied with the tissue and 18% of the tissues were sensitive to ara-C, 27% to BH-AC and 15% were sensitive to BH-AC but resistant to ara-C. Our findings show that ara-C and BH-AC are equally cytostatic to human tumors. The sensitivity test of ara-C and BH-AC enables one to determine which drug is best suited for individual patients.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalCHEMOTHERAPY
Volume35
Issue number3
DOIs
Publication statusPublished - Jan 1 1989

Fingerprint

Cytarabine
Neoplasms
Succinate Dehydrogenase
In Vitro Techniques
Lymphoma
Gastrointestinal Neoplasms
Cytostatic Agents

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

In vitro sensitivity of various human tumors to 1-beta-d-arabinofuranosy icy tosine and n4-behenoy 1-1-beta-d-arabinof uranosylcy tosine. / Maehara, Yoshihiko; Kusumoto, Tetsuya; Kusumoto, Hiroki; Anai, Hideaki; Sugimachi, Keizo.

In: CHEMOTHERAPY, Vol. 35, No. 3, 01.01.1989, p. 181-186.

Research output: Contribution to journalArticle

Maehara, Yoshihiko ; Kusumoto, Tetsuya ; Kusumoto, Hiroki ; Anai, Hideaki ; Sugimachi, Keizo. / In vitro sensitivity of various human tumors to 1-beta-d-arabinofuranosy icy tosine and n4-behenoy 1-1-beta-d-arabinof uranosylcy tosine. In: CHEMOTHERAPY. 1989 ; Vol. 35, No. 3. pp. 181-186.
@article{03e19e7d3cf646ef9272b0335de692d7,
title = "In vitro sensitivity of various human tumors to 1-beta-d-arabinofuranosy icy tosine and n4-behenoy 1-1-beta-d-arabinof uranosylcy tosine",
abstract = "The sensitivities to 1-β-D-arabinofuranosylcytosine (ara-C) and N4-behe-noyl-1-β-D-arabinofuranosylcytosine (BH-AC), a masked compound of ara-C, were determined in 33 human tumor tissues (11 gastric, 6 colorectal cancers and 16 malignant lymphomas), using the in vitro succinate dehydrogenase inhibition test. The succinate dehydrogenase (SD) activity of the tumor tissues was assayed following exposure to the drug at 8.8 or 88 μM for 3 days and the sensitivity was considered positive when the SD activity decreased to below 50{\%} of that of the control cells at 88 μM. The SD activity decreased little at 8.8 μM and decreased individually at 88 μM. The mean of the SD activity at 88 μM was 65.7 ± 11.5{\%} for ara-C and 61.4 ± 14.5{\%} for BH-AC in gastrointestinal cancers, and 63.8 ± 16.0{\%} for ara-C and 58.3 ± 18.3{\%} for BH-AC in malignant lymphomas with a statistically significant difference (p < 0.05). BH-AC is converted to ara-C for exertion of the cytotoxic effect and apositive correlation was noted between the SD activities of ara-C and BH-AC (r = 0.825 at88 μM). The chemosensitivity varied with the tissue and 18{\%} of the tissues were sensitive to ara-C, 27{\%} to BH-AC and 15{\%} were sensitive to BH-AC but resistant to ara-C. Our findings show that ara-C and BH-AC are equally cytostatic to human tumors. The sensitivity test of ara-C and BH-AC enables one to determine which drug is best suited for individual patients.",
author = "Yoshihiko Maehara and Tetsuya Kusumoto and Hiroki Kusumoto and Hideaki Anai and Keizo Sugimachi",
year = "1989",
month = "1",
day = "1",
doi = "10.1159/000238668",
language = "English",
volume = "35",
pages = "181--186",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - In vitro sensitivity of various human tumors to 1-beta-d-arabinofuranosy icy tosine and n4-behenoy 1-1-beta-d-arabinof uranosylcy tosine

AU - Maehara, Yoshihiko

AU - Kusumoto, Tetsuya

AU - Kusumoto, Hiroki

AU - Anai, Hideaki

AU - Sugimachi, Keizo

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The sensitivities to 1-β-D-arabinofuranosylcytosine (ara-C) and N4-behe-noyl-1-β-D-arabinofuranosylcytosine (BH-AC), a masked compound of ara-C, were determined in 33 human tumor tissues (11 gastric, 6 colorectal cancers and 16 malignant lymphomas), using the in vitro succinate dehydrogenase inhibition test. The succinate dehydrogenase (SD) activity of the tumor tissues was assayed following exposure to the drug at 8.8 or 88 μM for 3 days and the sensitivity was considered positive when the SD activity decreased to below 50% of that of the control cells at 88 μM. The SD activity decreased little at 8.8 μM and decreased individually at 88 μM. The mean of the SD activity at 88 μM was 65.7 ± 11.5% for ara-C and 61.4 ± 14.5% for BH-AC in gastrointestinal cancers, and 63.8 ± 16.0% for ara-C and 58.3 ± 18.3% for BH-AC in malignant lymphomas with a statistically significant difference (p < 0.05). BH-AC is converted to ara-C for exertion of the cytotoxic effect and apositive correlation was noted between the SD activities of ara-C and BH-AC (r = 0.825 at88 μM). The chemosensitivity varied with the tissue and 18% of the tissues were sensitive to ara-C, 27% to BH-AC and 15% were sensitive to BH-AC but resistant to ara-C. Our findings show that ara-C and BH-AC are equally cytostatic to human tumors. The sensitivity test of ara-C and BH-AC enables one to determine which drug is best suited for individual patients.

AB - The sensitivities to 1-β-D-arabinofuranosylcytosine (ara-C) and N4-behe-noyl-1-β-D-arabinofuranosylcytosine (BH-AC), a masked compound of ara-C, were determined in 33 human tumor tissues (11 gastric, 6 colorectal cancers and 16 malignant lymphomas), using the in vitro succinate dehydrogenase inhibition test. The succinate dehydrogenase (SD) activity of the tumor tissues was assayed following exposure to the drug at 8.8 or 88 μM for 3 days and the sensitivity was considered positive when the SD activity decreased to below 50% of that of the control cells at 88 μM. The SD activity decreased little at 8.8 μM and decreased individually at 88 μM. The mean of the SD activity at 88 μM was 65.7 ± 11.5% for ara-C and 61.4 ± 14.5% for BH-AC in gastrointestinal cancers, and 63.8 ± 16.0% for ara-C and 58.3 ± 18.3% for BH-AC in malignant lymphomas with a statistically significant difference (p < 0.05). BH-AC is converted to ara-C for exertion of the cytotoxic effect and apositive correlation was noted between the SD activities of ara-C and BH-AC (r = 0.825 at88 μM). The chemosensitivity varied with the tissue and 18% of the tissues were sensitive to ara-C, 27% to BH-AC and 15% were sensitive to BH-AC but resistant to ara-C. Our findings show that ara-C and BH-AC are equally cytostatic to human tumors. The sensitivity test of ara-C and BH-AC enables one to determine which drug is best suited for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=0024392658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024392658&partnerID=8YFLogxK

U2 - 10.1159/000238668

DO - 10.1159/000238668

M3 - Article

C2 - 2766858

AN - SCOPUS:0024392658

VL - 35

SP - 181

EP - 186

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 3

ER -